Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Altered Pupil Dynamics in Patients with Neurodegenerative Diseases
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
10-003

To characterize the changes to pupil dynamics in patients with neurodegenerative diseases associated with dementia
In neurodegenerative diseases, the progressive loss of brain matter leads to impairments in autonomic, motor, and cognitive functions. An easy-to-measure method that is increasingly used in clinical investigations to assess cognitive function is pupillometry. Pupil size is modulated by converging bottom-up sensory and top-down cognitive signals in addition to luminance and arousal. Furthermore, the circuitry for pupil control is linked to the saccade system. Therefore, disruptions in neural circuitry due to neurodegeneration may in turn affect pupil. 

Pupil size and eye position were recorded using the Eyelink1000 video-based eye-tracker while subjects performed 240 trials of the interleaved pro-/anti-saccade task. A total of 520 patients with diagnosis of one of 6 neurodegenerative diseases: Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and vascular cognitive impairment.
The pupil response following the presentation of the fixation cue consisted of an initial constriction component, which was mainly driven by the change of luminance from cue onset, followed by a dilation component that was previously linked to saccade suppression and voluntary saccade preparation. Analysis revealed distinct differences between patient groups and age-matched controls in pupil dynamics. Pupil constriction was reduced in the patient groups compared to controls as was pupil dilation, suggesting changes in the light reflex pathway and the top-down preparation signals, respectively. Furthermore, there were differences in pupil measurements among patient groups that may reflect differences between neurological diseases. The effects of medication and possible compensatory neurological changes to disease are also reflected in changes in pupil dynamics.
The results demonstrated changes in pupil dynamics linked to neurodegeneration, showing that pupil measurements in visuomotor tasks have the potential to provide relevant behavioural biomarker for diagnosis of neurodegenerative diseases and tracking disease progression.
Authors/Disclosures
Jeff Huang (Queen's University Centre for Neuroscience Studies)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Sandra E. Black, MD, FÂ鶹´«Ã½Ó³»­ (Sunnybrook Health Science Center) Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
Elizabeth Finger, MD, FÂ鶹´«Ã½Ó³»­ Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vigil Neuro. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali Therapeutics. The institution of Dr. Finger has received research support from CIHR. The institution of Dr. Finger has received research support from Physician Servcices Incorporated. The institution of Dr. Finger has received research support from Weston Foundation. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Annual Meeting Course Director with Â鶹´«Ã½Ó³»­.
Morris Freedman, MD, FÂ鶹´«Ã½Ó³»­ (Baycrest Health Sciences) No disclosure on file
Anthony E. Lang, MD, FÂ鶹´«Ã½Ó³»­ (Toronto Western Hospital) Dr. Lang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB. Dr. Lang has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for medicolegal cases related to paraquat. The institution of Dr. Lang has received research support from AbbVie. Dr. Lang has received intellectual property interests from a discovery or technology relating to health care. Dr. Lang has received publishing royalties from a publication relating to health care.
Michael J. Strong, MD, FÂ鶹´«Ã½Ó³»­ (London Health Sciences Centre) No disclosure on file
Richard H. Swartz, BSc MD PhD FRCPC (Sunnybrook Health Sciences Centre) The institution of Dr. Swartz has received research support from Heart and Stroke Foundation of Canada. The institution of Dr. Swartz has received research support from Ontario Brain Institute.
Carmela Tartaglia, MD (Toronto Western Hospital, University of Toronto) Dr. Tartaglia has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Tartaglia has received research support from NIH. The institution of Dr. Tartaglia has received research support from University of Toronto.
Lorne H. Zinman, MD Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, MTP, AB Science, Cytokinetics, Amylyx. Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx.
No disclosure on file